



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	294384	Curcumin 600 Plus
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Phytologic Holdings Pty Limited	
<b>Postal Address</b>	16-20 Baker Street, Banksmeadow, NSW, 2019 Australia	
<b>ARTG Start Date</b>	27/09/2017	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Curcumin 600 Plus

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	27/10/2021
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Antioxidant/Reduce free radicals formed in the body
- Helps reduce/decrease free radical damage to body cells
- Maintain/support general health and wellbeing
- Anti-inflammatory/relieve inflammation
- Decrease/reduce/relieve mild joint aches and pains
- Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis
- Decrease/reduce/relieve mild joint inflammation/swelling
- Maintain/support healthy digestive system function
- Maintain/support healthy digestion
- Maintain/support digestive system health
- Maintain/support healthy liver function

### Indication Requirements

- Product presentation must only refer to mild joint symptoms.
- Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.
- Label statement: If symptoms persist, talk to your health professional.
- Product presentation must not imply or refer to liver disease, such as cirrhosis, hepatitis.

### Standard Indications

No Standard Indications included on Record

### Specific Indications

No Specific Indications included on Record

### Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Public Summary



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

**Curcuma longa rhizome Extract dry concentrate standardised** **631.6 mg**

Equivalent: Curcuma longa (Dry) 15.79 g

**Piper nigrum fruit Extract dry concentrate** **5.26 mg**

Equivalent: Piper nigrum (Dry) 131.5 mg

**Other Ingredients (Excipients)**

colloidal anhydrous silica

hypromellose

magnesium stearate

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary